Spectrum Pharmaceuticals , Inc., a commercial-stage biotechnology company with a focus on oncology, develops and commercializes a portfolio of drug products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma (NHL); and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company is also developing apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products include Ozarelix, a drug being investigated for benign prostatic hypertrophy (BPH), a non-cancerous enlargement of the prostate, and hormone dependent prostate cancer; and Ortataxel, a third-generation taxane. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals
Insiders are buying
Revenues is start to pull inn
Net Income from Negativ to Positive
Positiv trend TA compare with the S&P500 last 3m
Best Regard
http://www.stockpicksexpert.com/
Free Stock Picks
Stock Investing Guide
God Investment
Real Estate Investing
Forex Trading
$5.55 (07/18/09)
